ReviewJournal of personalized medicine2023
Mechanisms of Allergen Immunotherapy and Potential Biomarkers for Clinical Evaluation.
Review in Journal of personalized medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06876506 (Identification and Quantitation of Human B Regulatory Cells Via Flow Cytometry and Their Potential Role as a Treatment Efficacy Biomarker in Allergen-specific Immunotherapy), which is not on this map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Identification and Quantitation of Human B Regulatory Cells Via Flow Cytometry and Their Potential Role as a Treatment Efficacy Biomarker in Allergen-specific Immunotherapy
Who cites it
30 citing papers in PubMed, 49 citations in OpenAlex.
- Bioassays in Allergy: Technical Characteristics, Limitations, and Pathways to Clinical Implementation-An EAACI Position Paper.Clinical and translational allergy · 2026Review
- Evaluation of sIgE Qualitative Conversion and Clinical Response to HDMs Sublingual Immunotherapy: Insights from Three Immunoassays.Biomolecules · 2026Article
- Immunological effects of subcutaneous and sublingual immunotherapy in house dust mite-allergic adults: a nine-month prospective pilot study.Scientific reports · 2026Article
- Review
- Linear Epitope-Mediated Immunological Cross-Reactivity in Livestock Product Allergens.International journal of molecular sciences · 2026Review
- Tolerance-guided dose adjustment in sublingual immunotherapy for children with dust mite-induced allergic rhinitis: a 6-month prospective cohort study.Frontiers in medicine · 2026Article
- Clinical Proteomics Applied to Food Allergy.Advances in experimental medicine and biology · 2026Review
- Comparative clinical efficacy and immunological modulation of subcutaneous vs. sublingual allergen immunotherapy in children with house dust mite-induced allergic asthma: a retrospective cohort study.Frontiers in medicine · 2026Article
- A novel oral immunotherapy strategy using transgenic barley inducesFrontiers in immunology · 2026Article
- Sublingual allergen immunotherapy: evidence from randomized trials, real-world studies and meta-analyses.Frontiers in allergy · 2026Review
- Prospective Evaluation of Specific IgE Profile and Quality-of-Life During Allergen-Specific Immunotherapy with House Dust Mite: A Pilot Study.Medicina (Kaunas, Lithuania) · 2025Article
- Advance in Managing Indoor Cat Allergen Proteins: Molecular Insights, Detection, and Control.International journal of molecular sciences · 2025Review
- Long-Term Administration of BTH2 Hypoallergenic Vaccine Candidate Induces Hallmarks of Allergen Immunotherapy in Murine Model ofBiomedicines · 2025Article
- Review
- Recombinant Hypoallergenic Cat Allergy Vaccines.Allergy · 2025Article
- Loss of Tolerance in Long-Term Allergen Immunotherapy: A Case of Late-Onset Systemic Anaphylaxis.Cureus · 2025Article
- Inhaled Allergy Diagnostics and Treatment in a Polluted Environment.International journal of molecular sciences · 2025Review
- Biomarker-driven drug development for allergic diseases and asthma: An FDA public workshop.The Journal of allergy and clinical immunology · 2025Article
- ARIA-Italy managing allergic rhinitis and asthma in a changing world: The role of the Pharmacist.The World Allergy Organization journal · 2025Review
- Allergen Immunotherapy: Pitfalls, Perks and Unexpected Allies.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 6 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Allergen-immunotherapy (AIT) is an efficacious and disease-modifying treatment option for IgE-mediated diseases. Among these allergic rhinitis, insect venom allergy, food allergy, and allergic asthma are the most common candidates for AIT. AIT gives rise to clinical immunotolerance which may last for years after the treatment cessation. Mechanisms of AIT include suppression of allergic inflammation in target tissues and stimulation of the production of blocking antibodies, especially IgG4 and IgA. These mechanisms are followed by a reduction of underlying allergen-specific Th2 cell-driven responses to the allergens. Tolerance induction takes place through the desensitization of effector cells and stimulation of regulatory T cells that show their effects by mechanisms involving cell-cell cross-talk, but also other mechanisms, e.g., by the production of immunomodulatory cytokines such as, e.g., IL-10 and TGF-beta. From a personalized medical perspective, there is a need for clinical biomarkers of value in selecting responders and optimizing patient care during AIT. Also, a deeper understanding of underlying mechanistic processes will improve AIT's future outcomes. In this paper, the current knowledge of mechanisms in AIT is reviewed with a special focus on biomarkers of this therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.